Major Pharmaceutical Markets of the Middle East

Summary

"Massive growth is being forecast for the pharmaceutical and biotechnology markets of Middle Eastern states, driven by moves to liberalise national economies, the introduction of mass health insurance and the determination of the region's governments to become self-sufficient in pharmaceuticals production."

Major Pharmaceutical Markets of the Middle East (2nd Edition) is a comprehensive report providing extensive coverage of one of the strongest emerging markets. Through quality analysis and forecasts, this unique report will allow you to identify market trends and growth potential opportunities.

This best-selling report provides the necessary background information for a firm to operate in the region.

Chapter summaries:

Chapter 1: covers the main characteristics of the Middle Eastern market through a Political, Economic, Social and Technological (PEST) analysis, plus insight into the tax environment and Free-Trade Agreements in place or being negotiated.

Chapter 2: reports on the Intellectual Property Rights environment of each of the countries covered.

Chapter 3: provides a overview of the regional pharmaceutical market, and includes data on consumption, production, imports, exports, as well as market forecasts.

The other chapters are in-depth per-country market studies.

Country coverage

• Egypt, the largest pharmaceutical market of the region
• Israel, home to the world's largest generic drug company
• Jordan, the leading Arab pharmaceutical exporter
• Lebanon, an almost exclusive import market
• Saudi Arabia, the largest market of the Gulf
• The United Arab Emirates, among the highest-priced markets in the region

Five key findings

• Overall the Middle East's pharmaceutical market is valued at more than $12bn and is expected to grow at healthy 10-15% annually.
• There are more than 450 pharmaceutical manufacturers in the Middle East - With the exception of Egypt, all Middle Eastern countries are high importers of branded drugs. Egypt is over 90% self-sufficient in its medicine needs
• Saudi Arabia, as the richest regional market, has embarked on an ambitious hospital building project - Major growth drivers are greater access to generics and innovative new medicines as primary care improves and more people are covered by health insurance.
• Countries are increasingly adopting liberal economic policies in the healthcare sector
• Local manufacturing capabilities are constrained to generics.
• A high acceptance of Western medicines is present

What you can learn from this repor

• Which multinationals have invested in the Middle East
• Who are the leading local pharmaceutical manufacturers and distributors
• What are the trends in the pharmaceutical market and import and export sizes
• How Intellectual Property Rights and patents are the most conflictual regional issue
• Which countries have implemented health insurance and the likely impact on growth
• What type of demand and supply-side cost controls are in place

Reasons to purchase the report

• Five-year projected sales figure to enable proprietary forecasting
• Detailed Political, Economic, Social and Technological (PEST) analysis providing thorough regional and country background
• Extensive list of local contacts to facilitate finding a potential business partner
• Thorough review of country pharmaceutical markets using latest available data
• Researched by a native speaker using primary and secondary data

Who should buy the report?

• Chief Executive Officers
• Marketing Directors
• Sales Directors
• Finance Directors
• Head of Commercial Strategy
• Head of Forecasting Unit
• Banking Analysts
• Consultants

About Author

A. Abderrahmane holds an MA in International Relations from the University of Durham and a BA in Politics & Geography from the School of Oriental & African Studies (SOAS), University of London. He is originally from Algeria and works as a freelance consultant.

Contents

• Executive Summary
• Chapter 1: Characteristics of the Middle Eastern Pharmaceutical Market: A Political, Economic, Social and Technological (PEST) Analysis
  • Political factors
  • Economic factors
  • Social factors
  • Technological factors
  • Free trade agreements
  • Euro-Mediterranean Free Trade Area (EU-MEFTA)
  • US-MEFTA (Middle East Free Trade Agreements)
  • Gulf Cooperation Council (GCC)
  • Taxation
  • Egypt
  • Israel
  • Jordan
  • Lebanon
  • Saudi Arabia
  • United Arab Emirates
• Chapter 2: Intellectual Property Rights
  • Trade-related Aspects of Intellectual Property Rights (TRIPS)
  • Egypt
  • Israel
  • Jordan
  • Lebanon
  • Saudi Arabia
  • United Arab Emirates
• Chapter 3: Overview of the Middle Eastern Pharmaceutical Market
  • Healthcare overview
  • Pharmaceutical consumption
  • Domestic production
  • Imports
  • Market forecast
• Chapter 4: Egypt
  • The healthcare structure
  • The pharmaceutical market
  • Market figures
  • Generics
  • Drug pricing and reimbursement
  • Distribution
  • Cost controls
  • Public tenders
  • Patient co-payment
  • Generic substitution
  • Leading companies
• Chapter 5: Israel
  • The healthcare structure
  • The pharmaceutical market
  • Market figures
  • Drug pricing and reimbursement
  • Distribution
  • Cost controls
  • Prescribing limitations
  • Generic substitution
  • Patient co-payment
  • Leading companies
  • Focus/point of interest: Teva
• Chapter 6: Jordan
  • The healthcare structure
  • Health equipment
  • The pharmaceutical market
  • Market figures
  • Focus/point of interest: medical tourism
  • Drug pricing and reimbursement
  • Distribution
  • Cost controls
  • Co-payment
  • Public-sector procurement
  • Leading companies
  • Focus/point of interest: Hikma
• Chapter 7: Lebanon
  • The healthcare structure
  • The pharmaceutical market
  • Market figures
  • Drug pricing and reimbursement
  • Distribution
  • Cost controls
  • Public procurement
  • National Drugs Office
  • Patient co-payment
  • Leading companies
• Chapter 8: Saudi Arabia
  • The healthcare structure
  • Pharmaceutical market
  • Market figures
  • Drug pricing and reimbursement
  • Distribution
  • Cost controls
  • Private health insurance provision
  • 'Dollarisation'
  • Gulf Cooperation Council bulk buying
  • Leading companies
• Chapter 9: United Arab Emirates
  • The healthcare structure
  • Pharmaceutical market
  • Market figures
  • Drug pricing and reimbursement
  • Distribution
  • Cost controls
  • Bulk buying
  • Co-payment
  • Leading companies
  • Focus/point of interest: Julphar
  • Focus/point of interest: Neopharma
  • Focus/point of interest: MENA
  • Abbreviations
• List of Tables
  • Table 2.1 Watch List status as at 2008
  • Table 3.1 Size of the pharmaceutical markets in selected countries of the Middle East
  • Table 3.2 Largest local pharmaceutical companies
  • Table 3.3 Leading generics players based on 2007 sales
  • Table 4.1 Egypt's consumer expenditure on health goods and medical services (LEm)
  • Table 4.2 Egypt's retail sales of OTC healthcare (LEm)
  • Table 5.1 Israel's consumer expenditure on health goods and medical services (NISm)
  • Table 5.2 Israel's retail sales of OTC healthcare (NISm)
  • Table 5.3 Teva's sales and net income
  • Table 6.1 Jordan's consumer expenditure on health goods and medical services (JDm)
  • Table 6.2 Jordan's retail sales of OTC healthcare (JDm)
  • Table 7.1 Lebanese retail sales of OTC healthcare (LLm)
  • Table 7.2 Lebanese consumer expenditure on health goods and medical services (LLm)
  • Table 8.1 Saudi Arabian consumer expenditure on health goods and medical services (SRm)
  • Table 8.2 Saudi Arabian retail sales of OTC healthcare (SRm)
  • Table 9.1 The UAE's consumer expenditure on health goods and medical services (AEDm)
  • Table 9.2 The UAE's retail sales of OTC healthcare (AEDm)
  • Table 9.3 Julphar sales and profits